This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Daniel E. Bergsagel, MD, D Phil; Waldemar Pruzanski, MD

Arch Intern Med. 1975;135(1):172-176.

Abstract
Because cross-resistance between alkylating agents has not been observed, we attempt in a prospective trial to determine the advantages, if any, in administering three alkylating agents sequentially, alternately, or concurrently.

A patient with myeloma, showing progressive shortening of M-protein doubling time from 98 to 15 days, developed an acute terminal phase, characterized by fever and pancytopenia. A similar acute terminal phase was observed in 17 of 50 deaths from myeloma. Since alkylating agents are only effective in controlling the chronic phase of myeloma, future improvements will require the discovery of agents that delay, prevent, or are effective in the treatment of the acute phase.

Forty-five patients with - and 36 with light-chain disease showed no differences in frequency of amyloidosis, renal failure, response to treatment, or survival after treatment with alkylating agents.

Author Affiliations
From the Department of Medicine, Ontario Cancer Institute and the University of Toronto (Dr. Bergsagel) and the Immunoglobulin Diagnostic and Research Centre, Department of Medicine, the University of Toronto (Dr. Pruzanski), Toronto.

Footnotes
Received for publication March 7, 1974; accepted May 16.

Read before the Symposium on Myeloma, Atlanta, Oct 22, 1973.

Reprint requests to 500 Sherbourne St, Toronto, Canada M4X 1K9 (Dr. Bergsagel).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Ten-Year Survival in Multiple Myeloma
Alexanian
Arch Intern Med 1985;145:2073-2074.
ABSTRACT  

Diffuse Aggressive Lymphomas: Increased Survival After Alternating Flexible Sequences of ProMACE and MOPP Chemotherapy
FISHER et al.
ANN INTERN MED 1983;98:304-309.
ABSTRACT  

Aggressive Phase of Multiple Myeloma With Pulmonary Plasma Cell Infiltrates
Garewal and Durie
JAMA 1982;248:1875-1876.
ABSTRACT  

Aggressive Terminal Phase of Multiple Myeloma
Blade et al.
Arch Intern Med 1982;142:1755-1755.
ABSTRACT  

In Reply.--
Coleman
Arch Intern Med 1982;142:1755-1756.
ABSTRACT  

Aggressive Plasma Cell Myeloma: A Terminal Phase
Suchman et al.
Arch Intern Med 1981;141:1315-1320.
ABSTRACT  

Monitoring Myelomatosis
Hobbs
Arch Intern Med 1975;135:125-130.
ABSTRACT